Dr Frischtak is NOT accepting new patients in private practice. For matters related to Ketamine treatment please go to www.ktcpartnership.com or use email firstname.lastname@example.org
Psychiatric Pharmacogenetic Testing:
CYP 450 genes testing in addition to other psychopharmacologically relevant gene testing
Dr Frischtak believes that psychiatric pharmacogenetic testing is a useful tool to personalize your treatment plan medication management wise. Dr Frischtak offers on site Cytochrome P450 (CYP450) genes testing in addition to other relevant genes to help determine which medication may be effective for each patient.
Polymorphic genes of the CYP450 family control the amount of active enzyme available to metabolize (process) many of the most common psychotropic medications. The results of Cytochrome P450 tests divide patients into four main types: poor metabolizers, normal metabolizers, intermediate metabolizers, ultrarapid metabolizers. This allows for better tailoring choice of medication as well as medication dosage adjustments. Other genes tested help determine family of medication that is more likely to be helpful among other relevant infornation regarding choice of medication.
Dr Frischtak generally recommends genetic testing when initial medication treatment isn't successful, medication treatment resistant cases, when a patient has a history of significant side effects while on medication or great sensitivity to dosage changes, children and adoelscents.
There are several clinical scenarios in which testing can be a very helpful tool in prescribing psychotropic medication.
The test is obtained by a cheek swab. Dr Frischtak or you will rub a cotton swab inside your cheek to retrieve a skin cell sample.